Intrinsiqs

Is Xeris Biopharma Holdings, Inc. overvalued?

Xeris Biopharma Holdings, Inc. (XERS) — key valuation metrics and fundamentals.

No verdict
Price
$9.83
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$1.70B
Dividend yield
0.0%
Return on equity
-426.3%
Sector
Healthcare

See the full interactive analysis →

Fair value compares XERS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.